At the last check on Thursday, Selecta Biosciences Inc.’s (NASDAQ:SELB) stock was up $0.02, moving up 1.38 percent to $1.11. The average number of shares traded per day over the past five days has been 686,080 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.0100 fall in that time frame. In the last twenty days, the average volume was 587,615, while in the previous 50 days, it was 987,220.
Since last month, SELB stock retreated -5.56%. Shares of the company fell to $1.0100 on 08/02/23, the lowest level in the past month. A 52-week high of $2.50 was reached on 02/14/23 after having rallying from a 52-week low of $0.90. Since the beginning of this year, SELB’s stock price has dropped by -2.21% or -$0.0200, and marked a new high 13 times. However, the stock has declined by -55.80% since its 52-week high.
SELB stock investors should be aware that Selecta Biosciences Inc. (SELB) stock had its last reported insider trading activity 224 days ago on Jan 05. Brunn Carsten, the President and CEO of the company, disposed of 13,473 shares for $1.13 on Jan 05. It resulted in a $15,214 divestment by the insider. TRABER PETER G sold 3,465 shares at an average price of $1.13 on Jan 05. The insider now owns 446,121 shares following the transaction. On Jan 05, Chief Scientific Officer Kishimoto Takashi Kei sold 3,392 shares at $1.13 apiece. The transaction was valued at $3,830.
Valuation Metrics
The stock’s beta is 1.11. Besides these, the trailing price-to-sales (P/S) ratio of 2.09, the price-to-book (PB) ratio of 2.26.
Financial Health
In the three months ended March 30, Selecta Biosciences Inc.’s quick ratio stood at 5.20, while its current ratio was 5.20, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.22, and the total debt-to-equity ratio was 0.35. In the year ended March 30, EBITDA margin amounted to 14.96%, whereas operating margins totaled -17.70%. Based on annual data, SELB earned $96.24 million in gross profit and brought in $110.78 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 12.60%. Return on equity (ROE) for the past 12 months was -17.60%.
In Selecta Biosciences Inc.’s quarter-end financial report for March 30, it reported total debt of $16.23 million. According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. SELB’s revenue fell -472.39% to $16.8 million during the quarter, while net income inched up to $5.94 million. While analysts expected Selecta Biosciences Inc. to report -$0.09 quarterly earnings, the actual figure was -$0.14 per share, beating the consensus estimate by -55.60%. During the quarter, the company generated -$18.25 million in EBITDA. The liabilities of Selecta Biosciences Inc. were 81.11 million at the end of its most recent quarter ended March 30, and its total debt was $37.73 million. The value of shareholders’ equity is $153.43 million.
Technical Picture
This quick technical analysis looks at Selecta Biosciences Inc.’s (SELB) price momentum. With a historical volatility rate of 64.10%, the RSI 9-day stood at 55.21% on 16 August.
With respect to its five-day moving average, the current Selecta Biosciences Inc. price is down by -0.89% percent or -$0.0100. At present, SELB shares trade -2.63% below its 20-day simple moving average and -21.28% percent below its 100-day simple moving average. However, the stock is currently trading approximately -20.71% below its SMA50 and -34.71% below its SMA200.
Stochastic coefficient K was 45.24% and Stochastic coefficient D was 34.92%, while ATR was 0.0669. Given the Stochastic reading of 71.43% for the 14-day period, the RSI (14) reading has been calculated as 52.09%.
Analyst Ratings
Needham reiterated its a Buy rating on Selecta Biosciences Inc. (NASDAQ: SELB) in a note to investors. The analysts firm has however raised their price target to $5, representing a possible 81.5% increase in the stock price. Selecta Biosciences Inc. (SELB) has been rated Buy by analysts. According to 0 brokerage firms, SELB is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Selecta Biosciences Inc. stock as buy, with 1 recommending it as overweight.
With a median target price of $4.00, the current consensus forecast for the stock is $4.00 – $4.00. Based on these forecasts, analysts predict Selecta Biosciences Inc. (SELB) will achieve an average price target of $4.00.
